Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
14 Jun 2022 | 03:35 pm |
Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.
Under the terms of the agreement, Myovant will receive an upfront payment of US$50 million, and is eligible to receive milestones which could total up to a further US$90.5 million. Myovant will continue to lead the global development of relugolix and provide initial product supply to Accord. Accord will be responsible for certain local clinical development, all commercialization for its territories, and has the option to manufacture relugolix in the future.
The Pinsent Masons transactions team was led by Life Sciences Transactions partner Gina Bicknell, with primary support from solicitor Kiah York and legal director Mario Subramaniam.
Key Contacts
Latest press releases
Show me all press releasesPinsent Masons advises DCC Energy on the acquisition of WIRSOL Roof Solutions
Multinational law firm Pinsent Masons has advised DCC Energy, a division of leading international sales, marketing and support services group DCC plc, on the acquisition of WIRSOL Roof Solutions (WIRSOL), a provider of photovoltaic (PV) and battery storage systems.
Pinsent Masons advises M Group Services on its buyout by CVC
Multinational law firm Pinsent Masons has advised M Group Services, the leading provider of essential infrastructure services in the UK and Ireland, on its sale to private equity house CVC.
Pinsent Masons lawyers appointed to the ICC International Court of Arbitration
Multinational law firm Pinsent Masons’ partner Sylvia Tonova and senior associate Chloé De Jager have been appointed as Members of the ICC International Court of Arbitration, as representatives for Bulgaria and South Africa respectively. Both new appointments are for a three-year term set to commence on 1 July 2024.
People who viewed this press release also viewed
Show me all press releasesPinsent Masons hires senior litigation and investigations partner Melanie Ryan in London
Multinational law firm Pinsent Masons has appointed litigation partner Melanie Ryan to join its Global Investigations team in London.
Pinsent Masons advises Sandoz on acquisition of remaining shares in Rowex Joint Venture
Multinational law firm Pinsent Masons has advised Sandoz on the acquisition of the remaining shares in Rowex Limited, a joint venture in Ireland between Sandoz and Rowa Pharmaceuticals.
Pinsent Masons hires Life Science partner in Dublin
Multinational law firm Pinsent Masons has hired transactional life sciences specialist Michael Stewart as partner in its Dublin office as it expands its pan-European Technology, Science and Industry (TSI) capabilities.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]